US Stock MarketDetailed Quotes

CVAC CureVac

Watchlist
  • 3.270
  • +0.160+5.14%
Close Jul 11 16:00 ET
  • 3.150
  • -0.120-3.67%
Post 19:58 ET
733.48MMarket Cap-2466P/E (TTM)

About CureVac Company

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Company Profile

SymbolCVAC
Company NameCureVac
Listing DateAug 14, 2020
Issue Price16.00
Founded2020
CEODr. Alexander Zehnder, M.B.A.,M.D.
MarketNASDAQ
Employees1126
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressFriedrich-Miescher-Strasse 15
CityTübingen
ProvinceBaden Wuerttemberg
CountryGermany
Zip Code72076
Phone49-7071-9883-0
Websitehttp://www.curevac.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Alexander Zehnder, M.B.A.,M.D.
  • Chief Executive Officer
  • 818.83K
  • Pierre Kemula
  • Chief Financial Officer
  • 654.18K
  • Myriam Mendila
  • Chief Development Officer
  • 581.80K
  • Malte Greune, PhD
  • Chief Operating Officer
  • 600.74K
  • Baron Jean Stephenne
  • Chairman of the Supervisory Board
  • 123.75K
  • Dr. Debra Stephanie Barker
  • Supervisory Director
  • 82.50K
  • Viola Bronsema, PhD
  • Supervisory Director
  • 68.75K
  • Klaus Schollmeier
  • Supervisory Director
  • 68.75K
  • Dr. Mathias Hothum, PhD
  • Supervisory Director
  • 96.25K
  • Craig A. Tooman
  • Supervisory Director
  • 96.25K
  • Michael Brosnan, B.Sc.
  • Independent Director
  • 51.03K
  • Dr. Igor Splawski, M.Sc.,PhD
  • chief scientific officer
  • 839.47K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg